SRPT - Sarepta TherapeuticsAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $96.76 | Open | $99.03 |
| Volume | 1.68M | Market Cap | 7.636B |
| Yield | Last Dividend |
| Duchenne Muscular Dystrophy (DMD) Treatm... | 01/14/21 |
| The Duchenne Muscular Dystrophy (DMD) Treatment Market is expected to have a highly positive outlook over the forecast period 2020-2027 according to a... | |
| Sarepta (SRPT) Looks Good: Stock Adds 9.... | 01/12/21 |
| Sarepta (SRPT) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes. | |
| SRPT EQUITY ALERT: ROSEN, GLOBAL INVESTO... | 01/09/21 |
| NEW YORK, Jan. 9, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on... | |
| Merrill Lynch Stick to Their Buy Rating ... | 01/09/21 |
| Merrill Lynch Stick to Their Buy Rating for Sarepta Therapeutics | |
| SRPT INVESTIGATION ALERT: Bernstein Lieb... | 01/08/21 |
| NEW YORK, Jan. 8, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities frau... | |
| INVESTIGATION ALERT: The Schall Law Firm... | 01/08/21 |
| LOS ANGELES--(BUSINESS WIRE)---- $SRPT #SRPT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeuti... | |
| SRPT EQUITY ALERT: Rosen Law Firm Announ... | 01/08/21 |
| NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of s... | |
| Tesla, Micron Technology, Sarepta Therap... | 01/08/21 |
| Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalitie... | |
| Sarepta Falls 50% To 10-Month Low After ... | 01/08/21 |
| Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT ), which had a lot riding on its gene therapy candidate for treating Duchenne muscular dystrophy in t... | |
| Stocks making the biggest moves in the p... | 01/08/21 |
| The stocks making the biggest moves in premarket trading include Tesla, Micron Technology, Sarepta Therapeutics & more. | |
| Needham Stick to Their Buy Rating for Sa... | 01/08/21 |
| Needham Stick to Their Buy Rating for Sarepta Therapeutics | |
| Mizuho Securities Stick to Their Buy Rat... | 01/08/21 |
| Mizuho Securities Stick to Their Buy Rating for Sarepta Therapeutics | |
| Leerink Partners Stick to Their Buy Rati... | 01/08/21 |
| Leerink Partners Stick to Their Buy Rating for Sarepta Therapeutics | |
| Biopharma Daily Stock Updates - 01/07/20 | 01/08/21 |
| $XBI $149.21 (+4.11%) ???? COVID: $NVAX (+3.56%) - Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine... | |
| Stocks making the biggest moves after ho... | 01/07/21 |
| Take a look at the stocks making notable moves in extended trading on Thursday. | |
| Biotech Bloodbath: Hedge Fund Hotel Sare... | 01/07/21 |
| Biotech Bloodbath: Hedge Fund Hotel Sarepta Collapses After Study Disappoints Not every stocks grows to the sky like Tesla (which just hit $835 after ... | |
| Sarepta stock plunges more than 50% afte... | 01/07/21 |
| Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mix... | |
| STAT+: Sarepta gene therapy for Duchenne... | 01/07/21 |
| Sarepta Therapeutics announced mixed results from the first randomized clinical trial of its gene therapy for Duchenne muscular dystrophy, raising que... | |
| Unusual Options Activity Insight: Sarept... | 01/04/21 |
| On Monday, shares of Sarepta Therapeutics (NASDAQ: SRPT) saw unusual options activity. After the option alert, the stock price moved up to $171.68. ??... | |
| Sarepta, Amicus Top Biotech Picks Ahead ... | 12/18/20 |
| Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc. (NA... | |
| Personalis Announces the Launch of SHERP... | 12/17/20 |
| MENLO PARK, Calif.--(BUSINESS WIRE)---- $SRPT #PrecisionOncology--Personalis Announces the Launch of SHERPA??? for High-Accuracy Neoantigen Prediction... | |
| JPMorgan says stocks are primed for sust... | 12/17/20 |
| Summary List Placement Despite the economic carnage caused by the worldwide COVID-19 outbreak, US stock indices have soared to all-time highs. That's ... | |
| Sarepta Therapeutics, Inc. (NASDAQ:SRPT)... | 12/15/20 |
| Sarepta Therapeutics, Inc. (NASDAQ:SRPT) insider Joseph Bratica sold 1,115 shares of the stock in a transaction on Friday, December 11th. The shares w... | |
| Sarepta Therapeutics Announces Executive... | 12/14/20 |
| -- Ian Estepan named chief financial officer-- Dallan Murray named chief commercial officer-- Louise Rodino-Klapac, Ph.D., named chief scientific offi... | |
| Should you invest in General Electric, S... | 12/07/20 |
| NEW YORK , Dec. 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GE, SRPT, CCL, BA, and CAT. ??? Full story available o... | |
| Merrill Lynch Stick to Their Buy Rating ... | 11/18/20 |
| Merrill Lynch Stick to Their Buy Rating for Sarepta Therapeutics | |
| This Is What Hedge Funds Bought And Sold... | 11/16/20 |
| This Is What Hedge Funds Bought And Sold In Q3: Complete 13F Summary Tyler Durden Mon, 11/16/2020 - 22:20 While we live in a time when the holdings of... | |
| RBC Capital Stick to Their Buy Rating fo... | 11/05/20 |
| RBC Capital Stick to Their Buy Rating for Sarepta Therapeutics | |
| Sarepta Therapeutics to Commence Dosing ... | 11/05/20 |
| -- Dosing with SRP-9001 commercial-process material to proceed following discussions with U.S. FDA -- -- Clinical dosing is expected to begin before t... | |
| Sarepta Therapeutics may delivered a pos... | 11/05/20 |
| Sarepta Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| Hold rating | 01/12/21 |
| Citigroup downgrades from Buy to Neutral rating and announces Price Target of $108.00 | |
| Strong Buy rating | 01/08/21 |
| SVB Leerink maintains Outperform rating and lowers Price Target from $197.00 to $125.00 | |
| Buy rating | 01/08/21 |
| Needham maintains Buy rating and lowers Price Target from $182.00 to $166.00 | |
| Hold rating | 01/08/21 |
| Morgan Stanley downgrades from Overweight to Equal-Weight rating and lowers Price Target from $182.00 to $95.00 | |
| Sell rating | 01/08/21 |
| JP Morgan downgrades from Overweight to Underweight rating and announces Price Target of $96.00 | |
| Hold rating | 01/08/21 |
| Credit Suisse maintains Neutral rating and lowers Price Target from $156.00 to $73.00 | |
| Hold rating | 12/14/20 |
| Credit Suisse maintains Neutral rating and lowers Price Target from $162.00 to $156.00 | |
| Hold rating | 11/11/20 |
| Berenberg initiates coverage with Hold rating and announces Price Target of $140.00 | |
| Strong Buy rating | 11/06/20 |
| SVB Leerink maintains Outperform rating and lowers Price Target from $214.00 to $197.00 | |
| Hold rating | 11/06/20 |
| Credit Suisse maintains Neutral rating and lowers Price Target from $167.00 to $162.00 | |
| Buy rating | 10/28/20 |
| UBS initiates coverage with Buy rating and announces Price Target of $212.00 | |
| Date | 2020-11-05 (AMC) | Est. (EPS/Rev.) | ($1.71)/ 137.43M |
| Actual (EPS/Rev.) | $-1.42/ $143.92 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Tech Trades | Tech Trades | 81.00 % | Follow |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| TechEvent Trading | TechEvent Investor | 61.00 % | Subscribe |
| BAWSDAQ | karan1703 | 60.00 % | Follow |
| King of Analysts (KoA) | King of Analysts | 60.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
